Dai un'occhiata al Libro degli ospiti
Pagina 1 - 30 di 15005 results
Nome Commento
Katie Newman

Posted at martedì, 19 agosto 2014 16:46 Visit posters website
Big Pharma And Medical Marijuana; How Can They Coexist?

Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
Summary

Companies like GW Pharmaceuticals has already established licensing with pharma companies abroad.
There still has yet to be a mass appeal for state side interest in the Life Sciences segment of medical marijuana.
GrowBLOX grow chamber recently arrived in Las Vegas allowing GBLX to officially cultivate a consistent medical grade product which could appeal in a similar way as GWPH.
There's opportunity for emerging companies to become acquisition or licensing targets for Big Pharma to come in within the near future as popular opinion shifts in support of alternative medicine.
Over the last few months, I've been closely following the marijuana industry. Anywhere from accessories to actual growing operations, this market has been a hotbed for analysis and speculation. Of course as with many developing sectors, marijuana has a long way to go before we start hearing about FDA approvals and big business taking a stand. What we have seen thus far, however, is the emergence of brand new companies mostly trading on the OTC who are becoming the mavericks of the MJ marketplace and possibly leading the way for big business and more importantly, Big Pharma to follow.

GrowBLOX (OTCQB:GBLX) Sciences has been a focus of mine, first based on the company's expansion model through partnerships in several marijuana friendly states, as well as the actual technology that GBLX has created. The GrowBLOX cultivation chamber is specifically designed to produce optimal environmental growing conditions for medical cannabis cultivation, and is the first chamber of its kind with the ability to monitor and control the growth process in order to produce high-grade medicinal marijuana. Up until this point, investors and on-lookers have only been able to view this through computer renderings and images of an empty box, which has lead to much speculation as to the actual operation of the technology and, in turn, the company.

Since early July, the stock has pulled back to prices as low as $1 (a price it hasn't seen since May) based on what I feel are concerns over the company's actual operations. It is pre-revenue and to this point, has been kept afloat through financing activities. Though partnerships have been in place and the company has hit several milestones especially in Nevada, I can say that based on responses to my own articles on the company, investors are looking for something more tangible.

On August 11 GB Sciences officially announced that the first GrowBLOX cultivation chamber had arrived in Las Vegas, NV. Furthermore, the company had stated that it will be posting images of the GrowBLOX™ along with a webcam feed of the growth process inside the cultivation chamber on their corporate website.

"Having our cutting-edge GrowBLOX™ chamber here is very exciting because it represents one important step towards completing our vision of a complete, proprietary GrowBLOX™ Cultivation Solution…Our GrowBLOX™ Cultivation Solutions will allow us to consistently grow toxin-free medical marijuana of the highest efficacy from harvest to harvest."

-Chief Science Officer Andrea Small-Howard, PhD, MBA-

So far GBLX has embedded itself in several key markets with the first being Nevada followed by Florida and the latest state to open its doors, Illinois. With the quick expansion of the company's footprint, the time has come for GBLX to see the rubber meet the road so to speak.

Since announcing this latest company development, GBLX stock has traded sideways and consistently in a price channel between $1.16-$1.22 in a relatively liquid market. This brings rise to what would appear to be a new lower support level for GBLX given that there's been so much accumulation in this current channel. This may also be something to look into more closely being that the chamber arrival is only one of what should be more over the coming months. Once medical sales begin, GB Sciences could be posting good revenue numbers given the market opportunity.

(click to enlarge)


Take Nevada for instance. GrowBLOX was 1 of only 18 companies that were approved for special licensing and more importantly, the company's Fort Apache location is the only dispensary to service the needs of patients in that area, making the special use permit license all the more important for Clark County and for GBLX. In looking at the overall market within Nevada, it appears that medical operators have the potential to make a lot more on the sale of marijuana as compared to other states based on the taxes imposed; Nevada is at a mere 2%.

There've been many comments both positive and negative regarding the actual operation of the company and after the announcement on the arrival of the cultivation chamber, this gives rise to the company's ability to start growing proprietary strains to distribute to its dispensaries and partner dispensaries. For GBLX and the industry as a whole, the arrival of this first GrowBLOX chamber signals a new way for cannabis cultivation consistency.

In a recent video of GrowBLOX CFO, Steven Weldon, he's of the thought that through this new way of consistent medical marijuana cultivation, there will be a new standard set that could ultimately compete with Big Pharma. Mr. Weldon states that marijuana is not based so much on "getting high" but is based more on quality of life and making a medical product.

Comparatively speaking, look at a company like GW Pharmaceuticals (NASDAQ:GWPH), which has a product portfolio of cannabinoid prescription medicines to meet patient needs "in a wide range of therapeutic indications". GW trades on the Nasdaq and IPO'd at $8.90 in May 2013. The company states that it's focused on the Life Science space instead of the class of 'Medical Marijuana'. GW has entered into five separate licensing agreements for its Sativex product with Bayer HealthCare (a subsidiary of Bayer AG) in the UK and Canada; Almirall (ALM.ES) in Europe (excluding the UK) and Mexico; Otsuka Pharmaceutical Co. Ltd in the United States; Novartis AG (NYSE:NVS) in the Middle East (excluding Israel), Africa, and Asia (excluding China and Japan); and with Neopharm in Israel.

In its Q3 filing, GW realized an increase in revenue to $13million, up 4% from the previous quarter. In addition to this, the company openly states that its shown a net loss on the books due to increased R&D. However, this R&D has lead to both phase 2 and phase 3 testing of the company's proprietary products for treatment of anything from cancer pain to epilepsy. Furthermore, over the course of the last 3 months, GWPH has increased in share price from lows of $63 in May to as high as $111.46 during the first week of July. Currently the stock sits around $93 a share following the turnover from the late June- early July rally.

When considering medical marijuana as more of a life science as opposed to a drug, there's obvious potential in the marketplace especially abroad as indicated by GW's progress with licensing to pharmaceutical companies outside of the US. While the nation continues to litigate the rollout of an effective policy for this new industry, companies like GrowBLOX and GW Pharma have identified a more viable approach to growth within the space. By being able to provide pharmaceutical grade products, the opportunity for licensing and partnerships becomes more evident as the much larger GWPH suggests. I would imagine that if there was a way to mass-produce strains of marijuana like Johnson and Johnson produces Tylenol and Bayer Produces aspirin, the industry as a whole could be in for a big change with the benefits being realized by patients in need.

It will be an interesting third quarter moving forward for GBLX because not only will the company be actively growing its proprietary strains but also other states will have an opportunity to vote on and potentially implement medical and recreational programs. I think for both GW Pharma and GB Sciences, the real opportunity will be the ability to produce a consistent, medical grade product that big pharma companies can either license or simply purchase at wholesale. If GWPH is any example of what an emerging company like GBLX can become, the future should be brighter as GrowBLOX continues to implement more R & D for medical-grade marijuana cultivation as well as proprietary cannabinoid extraction methodologies. Currently, under the scientific direction of Dr. Andrea Small-Howard, PhD, MBA, the company will be pursuing a "biphasic product pipeline strategy" involving a near-term accelerated development plan; as well as a longer-term commitment to build a traditional product development pipeline.

According to GB Sciences, the company will utilize its patent-pending cultivation technology and a simultaneous two-phase approach to create a cannabinoid product development pipeline. Once initiated, GBLX states that it will be able to provide FDA-approved cannabis-therapy options to patients in a shorter time frame, which will also accelerate the time to a return on the company's investment. In the most recent quarterly filing GB states, "Our initial phase will be the accelerated "virtual pharma" and will include obtaining license patents on promising projects, testing and FDA approval, and co-developing the resulting product for marketing and sale. The next phase will involve setting up a traditional biopharmaceutical research method to allow out company to begin the R&D process in-house and fully own resulting patents and products."

In comparison to GW Pharma and what GB Sciences could become, the upside does not come without risk especially during the early stages that the company is in right now. Even though they have over $3million in cash, all of the company's operations have been backed by heavy financing activities and up until this point, there are zero revenues to report. In addition to this, GB also states in their Q that the company will require even more operating cash through 2015 to the tune of more than $4million.

Potential investment risks also include the overall market risk which is quite obvious when thinking about dilution. Despite the positive sentiment driven by outside institutional investors like Lazarus Partners, building a position from stock purchases directly through the market, I think investors should err on the side of caution when making their own investment decisions. Know that unlike GW Pharma, GBLX is in its development stage and even with the established partnerships in Nevada, Illinois, and Florida the company still needs to produce an actual product. Notwithstanding these risks, I think that the arrival of the actual chamber should be the first stepping stone to moving forward in producing revenues.

Finally, with the size of the marijuana industry set to grow by billions of dollars over the next 5 years, I'm sure that once there is an established market at the national level, we should start to see some of the smaller companies take an increased market share by the time industries like Big Pharma begin to actually enter the space.

Editor's Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
 
Katie Newman

Posted at martedì, 19 agosto 2014 16:30 Visit posters website
Big Pharma And Medical Marijuana; How Can They Coexist?

Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
Summary

Companies like GW Pharmaceuticals has already established licensing with pharma companies abroad.
There still has yet to be a mass appeal for state side interest in the Life Sciences segment of medical marijuana.
GrowBLOX grow chamber recently arrived in Las Vegas allowing GBLX to officially cultivate a consistent medical grade product which could appeal in a similar way as GWPH.
There's opportunity for emerging companies to become acquisition or licensing targets for Big Pharma to come in within the near future as popular opinion shifts in support of alternative medicine.
Over the last few months, I've been closely following the marijuana industry. Anywhere from accessories to actual growing operations, this market has been a hotbed for analysis and speculation. Of course as with many developing sectors, marijuana has a long way to go before we start hearing about FDA approvals and big business taking a stand. What we have seen thus far, however, is the emergence of brand new companies mostly trading on the OTC who are becoming the mavericks of the MJ marketplace and possibly leading the way for big business and more importantly, Big Pharma to follow.

GrowBLOX (OTCQB:GBLX) Sciences has been a focus of mine, first based on the company's expansion model through partnerships in several marijuana friendly states, as well as the actual technology that GBLX has created. The GrowBLOX cultivation chamber is specifically designed to produce optimal environmental growing conditions for medical cannabis cultivation, and is the first chamber of its kind with the ability to monitor and control the growth process in order to produce high-grade medicinal marijuana. Up until this point, investors and on-lookers have only been able to view this through computer renderings and images of an empty box, which has lead to much speculation as to the actual operation of the technology and, in turn, the company.

Since early July, the stock has pulled back to prices as low as $1 (a price it hasn't seen since May) based on what I feel are concerns over the company's actual operations. It is pre-revenue and to this point, has been kept afloat through financing activities. Though partnerships have been in place and the company has hit several milestones especially in Nevada, I can say that based on responses to my own articles on the company, investors are looking for something more tangible.

On August 11 GB Sciences officially announced that the first GrowBLOX cultivation chamber had arrived in Las Vegas, NV. Furthermore, the company had stated that it will be posting images of the GrowBLOX™ along with a webcam feed of the growth process inside the cultivation chamber on their corporate website.

"Having our cutting-edge GrowBLOX™ chamber here is very exciting because it represents one important step towards completing our vision of a complete, proprietary GrowBLOX™ Cultivation Solution…Our GrowBLOX™ Cultivation Solutions will allow us to consistently grow toxin-free medical marijuana of the highest efficacy from harvest to harvest."

-Chief Science Officer Andrea Small-Howard, PhD, MBA-

So far GBLX has embedded itself in several key markets with the first being Nevada followed by Florida and the latest state to open its doors, Illinois. With the quick expansion of the company's footprint, the time has come for GBLX to see the rubber meet the road so to speak.

Since announcing this latest company development, GBLX stock has traded sideways and consistently in a price channel between $1.16-$1.22 in a relatively liquid market. This brings rise to what would appear to be a new lower support level for GBLX given that there's been so much accumulation in this current channel. This may also be something to look into more closely being that the chamber arrival is only one of what should be more over the coming months. Once medical sales begin, GB Sciences could be posting good revenue numbers given the market opportunity.

(click to enlarge)


Take Nevada for instance. GrowBLOX was 1 of only 18 companies that were approved for special licensing and more importantly, the company's Fort Apache location is the only dispensary to service the needs of patients in that area, making the special use permit license all the more important for Clark County and for GBLX. In looking at the overall market within Nevada, it appears that medical operators have the potential to make a lot more on the sale of marijuana as compared to other states based on the taxes imposed; Nevada is at a mere 2%.

There've been many comments both positive and negative regarding the actual operation of the company and after the announcement on the arrival of the cultivation chamber, this gives rise to the company's ability to start growing proprietary strains to distribute to its dispensaries and partner dispensaries. For GBLX and the industry as a whole, the arrival of this first GrowBLOX chamber signals a new way for cannabis cultivation consistency.

In a recent video of GrowBLOX CFO, Steven Weldon, he's of the thought that through this new way of consistent medical marijuana cultivation, there will be a new standard set that could ultimately compete with Big Pharma. Mr. Weldon states that marijuana is not based so much on "getting high" but is based more on quality of life and making a medical product.

Comparatively speaking, look at a company like GW Pharmaceuticals (NASDAQ:GWPH), which has a product portfolio of cannabinoid prescription medicines to meet patient needs "in a wide range of therapeutic indications". GW trades on the Nasdaq and IPO'd at $8.90 in May 2013. The company states that it's focused on the Life Science space instead of the class of 'Medical Marijuana'. GW has entered into five separate licensing agreements for its Sativex product with Bayer HealthCare (a subsidiary of Bayer AG) in the UK and Canada; Almirall (ALM.ES) in Europe (excluding the UK) and Mexico; Otsuka Pharmaceutical Co. Ltd in the United States; Novartis AG (NYSE:NVS) in the Middle East (excluding Israel), Africa, and Asia (excluding China and Japan); and with Neopharm in Israel.

In its Q3 filing, GW realized an increase in revenue to $13million, up 4% from the previous quarter. In addition to this, the company openly states that its shown a net loss on the books due to increased R&D. However, this R&D has lead to both phase 2 and phase 3 testing of the company's proprietary products for treatment of anything from cancer pain to epilepsy. Furthermore, over the course of the last 3 months, GWPH has increased in share price from lows of $63 in May to as high as $111.46 during the first week of July. Currently the stock sits around $93 a share following the turnover from the late June- early July rally.

When considering medical marijuana as more of a life science as opposed to a drug, there's obvious potential in the marketplace especially abroad as indicated by GW's progress with licensing to pharmaceutical companies outside of the US. While the nation continues to litigate the rollout of an effective policy for this new industry, companies like GrowBLOX and GW Pharma have identified a more viable approach to growth within the space. By being able to provide pharmaceutical grade products, the opportunity for licensing and partnerships becomes more evident as the much larger GWPH suggests. I would imagine that if there was a way to mass-produce strains of marijuana like Johnson and Johnson produces Tylenol and Bayer Produces aspirin, the industry as a whole could be in for a big change with the benefits being realized by patients in need.

It will be an interesting third quarter moving forward for GBLX because not only will the company be actively growing its proprietary strains but also other states will have an opportunity to vote on and potentially implement medical and recreational programs. I think for both GW Pharma and GB Sciences, the real opportunity will be the ability to produce a consistent, medical grade product that big pharma companies can either license or simply purchase at wholesale. If GWPH is any example of what an emerging company like GBLX can become, the future should be brighter as GrowBLOX continues to implement more R & D for medical-grade marijuana cultivation as well as proprietary cannabinoid extraction methodologies. Currently, under the scientific direction of Dr. Andrea Small-Howard, PhD, MBA, the company will be pursuing a "biphasic product pipeline strategy" involving a near-term accelerated development plan; as well as a longer-term commitment to build a traditional product development pipeline.

According to GB Sciences, the company will utilize its patent-pending cultivation technology and a simultaneous two-phase approach to create a cannabinoid product development pipeline. Once initiated, GBLX states that it will be able to provide FDA-approved cannabis-therapy options to patients in a shorter time frame, which will also accelerate the time to a return on the company's investment. In the most recent quarterly filing GB states, "Our initial phase will be the accelerated "virtual pharma" and will include obtaining license patents on promising projects, testing and FDA approval, and co-developing the resulting product for marketing and sale. The next phase will involve setting up a traditional biopharmaceutical research method to allow out company to begin the R&D process in-house and fully own resulting patents and products."

In comparison to GW Pharma and what GB Sciences could become, the upside does not come without risk especially during the early stages that the company is in right now. Even though they have over $3million in cash, all of the company's operations have been backed by heavy financing activities and up until this point, there are zero revenues to report. In addition to this, GB also states in their Q that the company will require even more operating cash through 2015 to the tune of more than $4million.

Potential investment risks also include the overall market risk which is quite obvious when thinking about dilution. Despite the positive sentiment driven by outside institutional investors like Lazarus Partners, building a position from stock purchases directly through the market, I think investors should err on the side of caution when making their own investment decisions. Know that unlike GW Pharma, GBLX is in its development stage and even with the established partnerships in Nevada, Illinois, and Florida the company still needs to produce an actual product. Notwithstanding these risks, I think that the arrival of the actual chamber should be the first stepping stone to moving forward in producing revenues.

Finally, with the size of the marijuana industry set to grow by billions of dollars over the next 5 years, I'm sure that once there is an established market at the national level, we should start to see some of the smaller companies take an increased market share by the time industries like Big Pharma begin to actually enter the space.

Editor's Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
 
thomson

Posted at martedì, 19 agosto 2014 05:24 Visit posters website
When it came time to Knowledge.
 
yamahot

Posted at giovedì, 14 agosto 2014 04:31 Visit posters website
Information of your site is useful and knowledgeable about most
 
Jacquie

Posted at martedì, 12 agosto 2014 21:10 Visit posters website
Thanks for supplying many of these awesome written content.
 
Katie Newman

Posted at lunedì, 28 luglio 2014 14:38 Visit posters website
NHLE Distributor Hits Ground Running and Begins Signing Retailers

HOUSTON---

Nhale (NHLE) announces the new distributor it brought on board last week, Evaps Distribution and Promotions, has signed several retailers who will sell Nhale’s multi-use vape pen kits. With a goal of selling the first 10,000 units within a compressed timeframe, Evaps has agreed to market the vaporizer pen kits to a wide variety of retailers.

“For such a young company, Evaps is really taking it to the street and showing early results in getting our product in front of consumers,” said Lance Williams, President and CEO of Nhale. He added, “We feel the infrastructure of Evaps is conducive to moving rapidly, as we work to capitalize on the huge trends that will drive demand for our product.”

According to an interview with a marijuana entrepreneur in USA Today, advances in extracting active ingredients from cannabis plants have given rise to the popularity of portable vaporizer technology such as Nhale’s multi-use vape pen. The article cites roughly 50% of legal dispensary business is now in the form of edibles and concentrates, such as those used in vaporizer devices.

The Nhale vaporizer features interchangeable parts for dry leaf material and a glass chamber for oils and concentrates in an elegant, lightweight, pen-style vape. The Nhale device draws its power from a durable lithium ion battery. The parts are contained in a compact case for maximum portability.

For more information about retail opportunities or sales, visit **

About Nhale, Inc. (NHLE)

Nhale™ is a technology company that plans to launch commercial products in the consumer space while focusing on two significant trends occurring in the U.S. and around the world:

The adoption of vaporizing and electronic cigarettes, or ecigs, by the world's 1 billion+ smokers, and
The decriminalization and legalization of marijuana for medicinal or recreational purposes.
More information about Nhale is found at **

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of any past success, either financial or strategic, is no guarantee of future success. This news release only speaks as of the date of its distribution.


Contact:
Nhale, Inc.
Lance Williams, 281-671-6877
President and CEO
 
Katie Newman

Posted at lunedì, 28 luglio 2014 14:29 Visit posters website
NHLE Distributor Hits Ground Running and Begins Signing Retailers

HOUSTON---

Nhale (NHLE) announces the new distributor it brought on board last week, Evaps Distribution and Promotions, has signed several retailers who will sell Nhale’s multi-use vape pen kits. With a goal of selling the first 10,000 units within a compressed timeframe, Evaps has agreed to market the vaporizer pen kits to a wide variety of retailers.

“For such a young company, Evaps is really taking it to the street and showing early results in getting our product in front of consumers,” said Lance Williams, President and CEO of Nhale. He added, “We feel the infrastructure of Evaps is conducive to moving rapidly, as we work to capitalize on the huge trends that will drive demand for our product.”

According to an interview with a marijuana entrepreneur in USA Today, advances in extracting active ingredients from cannabis plants have given rise to the popularity of portable vaporizer technology such as Nhale’s multi-use vape pen. The article cites roughly 50% of legal dispensary business is now in the form of edibles and concentrates, such as those used in vaporizer devices.

The Nhale vaporizer features interchangeable parts for dry leaf material and a glass chamber for oils and concentrates in an elegant, lightweight, pen-style vape. The Nhale device draws its power from a durable lithium ion battery. The parts are contained in a compact case for maximum portability.

For more information about retail opportunities or sales, visit **

About Nhale, Inc. (NHLE)

Nhale™ is a technology company that plans to launch commercial products in the consumer space while focusing on two significant trends occurring in the U.S. and around the world:

The adoption of vaporizing and electronic cigarettes, or ecigs, by the world's 1 billion+ smokers, and
The decriminalization and legalization of marijuana for medicinal or recreational purposes.
More information about Nhale is found at **

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of any past success, either financial or strategic, is no guarantee of future success. This news release only speaks as of the date of its distribution.


Contact:
Nhale, Inc.
Lance Williams, 281-671-6877
President and CEO
 
Mitchell Wessendorf

Posted at domenica, 27 luglio 2014 01:06 Visit posters website
Generating an income online today is simpler than in the past due to more and more people operating on the net. At once customers had been hesitant to order online, however it is actually a lot more secure and folks are warming up to the idea of giving credit card information on-line. If you would like to generate income on the web and searching for very good guidelines on how to do so, then read more under.
 
Katie Newman

Posted at venerdì, 25 luglio 2014 18:19 Visit posters website
GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois

LAS VEGAS, July 25, 2014 -- GrowBLOX Sciences, Inc. (GBLX) is pleased to announce the execution of a binding Memorandum of Understanding ("MOU") with LaurelCo, LLC, an Illinois limited liability company formed to pursue the acquisition of both cultivation and dispensary medical marijuana licenses in the state of Illinois. Pursuant to the MOU, GBLX will acquire a 20% equity interest in LaurelCo, LLC in exchange for licenses to use our proprietary GrowBLOXTM growing chambers, as well as all technology related to the machines and to various other proprietary technologies ("GrowBLOXTM Solutions") required for the cloning, growing, curing, and creation of pharmaceutical grade medical marijuana. Further, GBLX will provide technical assistance during the upcoming complex Illinois license application process. The MOU further provides that after LaurelCo, LLC has received one or more licenses in the state, GBLX will provide growing chambers for the LaurelCo, LLC's growing facilities, in exchange for an accelerated payback of actual costs, plus a 10% royalty interest going forward in any products created in the chambers and sold by the LaurelCo, LLC licensed entity.

Laurel Dineff, CEO and principal of LaurelCo, LLC said, "We are extremely excited about our new arrangement with GBLX. We have expended considerable resources in developing our plan for medical marijuana growth in this great state of Illinois. After exhaustive research, we have concluded that GBLX has not only the best growing technology, but also the best approach to making medical marijuana the serious pharmaceutical it should be to treat the many maladies for which it has proven to be effective."

Craig Ellins, CEO of GBLX, stated, "We could not be more pleased to have this partnership with LaurelCo, LLC. The resources that its principals have made available to it, the prodigious quantity of good work that has already been done in terms of obtaining real property and other facilities necessary for the business, and the wonderful attitude of LaurelCo, LLC's management will make for a successful licensing effort and a prosperous and exemplary business. Moreover," he continued, "the agreement with LaurelCo, LLC represents a clear step forward in the GBLX strategy to create a nationwide supply of pharmaceutical grade and branded medical marijuana that is consistent and efficacious no matter where it is grown. With the formalization of our relationship with LaurelCo, LLC in Illinois, we are setting a standard for our growth into states in which GBLX does not have resources in place to operate a medical marijuana business by seeking out great partnerships who will operate the local business and be part of our nationwide plans."

About GrowBLOX Sciences, Inc.
GrowBLOX Sciences, Inc., is a research and biotechnical company that has developed proprietary indoor growing chambers specifically designed for medical cannabis cultivation. The GrowBLOXTM chamber allows for completely controlled growing conditions, ensuring the manufacture of a consistent, toxin-free, natural and medicinal-grade product. The Company believes that the advantages of a controlled environment over traditional outdoor or greenhouse growing, will empower the public, nutraceutical and pharmaceutical industries to embrace cannabis as an effective treatment for a myriad of serious medical conditions. gbsciences.com

Forward-Looking Statements
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Jonathan Barkman
Riverview Capital Enterprises
+1-866-845-0105
 
Katie Newman

Posted at venerdì, 25 luglio 2014 18:04 Visit posters website
GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois

LAS VEGAS, July 25, 2014 -- GrowBLOX Sciences, Inc. (GBLX) is pleased to announce the execution of a binding Memorandum of Understanding ("MOU") with LaurelCo, LLC, an Illinois limited liability company formed to pursue the acquisition of both cultivation and dispensary medical marijuana licenses in the state of Illinois. Pursuant to the MOU, GBLX will acquire a 20% equity interest in LaurelCo, LLC in exchange for licenses to use our proprietary GrowBLOXTM growing chambers, as well as all technology related to the machines and to various other proprietary technologies ("GrowBLOXTM Solutions") required for the cloning, growing, curing, and creation of pharmaceutical grade medical marijuana. Further, GBLX will provide technical assistance during the upcoming complex Illinois license application process. The MOU further provides that after LaurelCo, LLC has received one or more licenses in the state, GBLX will provide growing chambers for the LaurelCo, LLC's growing facilities, in exchange for an accelerated payback of actual costs, plus a 10% royalty interest going forward in any products created in the chambers and sold by the LaurelCo, LLC licensed entity.

Laurel Dineff, CEO and principal of LaurelCo, LLC said, "We are extremely excited about our new arrangement with GBLX. We have expended considerable resources in developing our plan for medical marijuana growth in this great state of Illinois. After exhaustive research, we have concluded that GBLX has not only the best growing technology, but also the best approach to making medical marijuana the serious pharmaceutical it should be to treat the many maladies for which it has proven to be effective."

Craig Ellins, CEO of GBLX, stated, "We could not be more pleased to have this partnership with LaurelCo, LLC. The resources that its principals have made available to it, the prodigious quantity of good work that has already been done in terms of obtaining real property and other facilities necessary for the business, and the wonderful attitude of LaurelCo, LLC's management will make for a successful licensing effort and a prosperous and exemplary business. Moreover," he continued, "the agreement with LaurelCo, LLC represents a clear step forward in the GBLX strategy to create a nationwide supply of pharmaceutical grade and branded medical marijuana that is consistent and efficacious no matter where it is grown. With the formalization of our relationship with LaurelCo, LLC in Illinois, we are setting a standard for our growth into states in which GBLX does not have resources in place to operate a medical marijuana business by seeking out great partnerships who will operate the local business and be part of our nationwide plans."

About GrowBLOX Sciences, Inc.
GrowBLOX Sciences, Inc., is a research and biotechnical company that has developed proprietary indoor growing chambers specifically designed for medical cannabis cultivation. The GrowBLOXTM chamber allows for completely controlled growing conditions, ensuring the manufacture of a consistent, toxin-free, natural and medicinal-grade product. The Company believes that the advantages of a controlled environment over traditional outdoor or greenhouse growing, will empower the public, nutraceutical and pharmaceutical industries to embrace cannabis as an effective treatment for a myriad of serious medical conditions. gbsciences.com

Forward-Looking Statements
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Jonathan Barkman
Riverview Capital Enterprises
+1-866-845-0105
 
Hallie Doshi

Posted at venerdì, 25 luglio 2014 04:16 Visit posters website
Generating an income online right now is easier than ever as a result of so many people operating online. At some point customers have been reluctant to buy online, the good news is it is actually significantly less dangerous and individuals are warming up to the concept of supplying visa or mastercard information and facts on the web. If you would like to make money on the web and searching for excellent tips on how to do so, then keep reading listed below.
 
Katie Newman

Posted at giovedì, 24 luglio 2014 18:13 Visit posters website
NHLE Signs Evaps as Distributor

Nhale (NHLE) announces it has signed Evaps Distribution and Promotions as a distributor for Nhale’s multi-use vape pen kit. Evaps has agreed to sell the pen kits to retailers across the country and has placed an initial order of 10,000 units to be shipped incrementally during the coming months.

“These game-changing devices are producing a booming industry and a shift in consumer demand,” said Lance Williams, President and CEO of Nhale. He added, “This transformative technology has come during a time when marijuana is quickly gaining legal and public acceptance, putting us in the midst of two major trends.”

Just as ecigs are bringing major change to the tobacco industry, vaporizers—the ecigarettes of the marijuana world—are transforming that space. According to USA Today, roughly half of the marijuana sold in legal U.S. dispensaries is in the form of edibles and concentrates, many of which are used for vaping. In New York, the twenty-third state to legalize medical marijuana, it can only be prescribed in non-smokable forms, including pills, oils and vapors. These limited options may potentially increase the demand for vaping devices in that state.

The Nhale vaporizer features interchangeable parts for dry leaf herbs and a glass chamber for oils and concentrates in an elegant, lightweight, pen-style vape. The Nhale device draws its power from a durable lithium ion battery. The parts are contained in a compact case for maximum portability.

For more information about retail opportunities or sales, visit **

About Nhale, Inc. (NHLE)

Nhale™ is a technology company that plans to launch commercial products in the consumer space while focusing on two significant trends occurring in the U.S. and around the world:

The adoption of vaporizing and electronic cigarettes, or ecigs, by the world's 1 billion+ smokers, and
The decriminalization and legalization of marijuana for medicinal or recreational purposes.
More information about Nhale is found at **

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of any past success, either financial or strategic, is no guarantee of future success. This news release only speaks as of the date of its distribution.


Contact:
Nhale, Inc.
Lance Williams, 281-671-6877
President and CEO
 
Katie Newman

Posted at giovedì, 24 luglio 2014 17:23 Visit posters website
NHLE Signs Evaps as Distributor

Nhale (NHLE) announces it has signed Evaps Distribution and Promotions as a distributor for Nhale’s multi-use vape pen kit. Evaps has agreed to sell the pen kits to retailers across the country and has placed an initial order of 10,000 units to be shipped incrementally during the coming months.

“These game-changing devices are producing a booming industry and a shift in consumer demand,” said Lance Williams, President and CEO of Nhale. He added, “This transformative technology has come during a time when marijuana is quickly gaining legal and public acceptance, putting us in the midst of two major trends.”

Just as ecigs are bringing major change to the tobacco industry, vaporizers—the ecigarettes of the marijuana world—are transforming that space. According to USA Today, roughly half of the marijuana sold in legal U.S. dispensaries is in the form of edibles and concentrates, many of which are used for vaping. In New York, the twenty-third state to legalize medical marijuana, it can only be prescribed in non-smokable forms, including pills, oils and vapors. These limited options may potentially increase the demand for vaping devices in that state.

The Nhale vaporizer features interchangeable parts for dry leaf herbs and a glass chamber for oils and concentrates in an elegant, lightweight, pen-style vape. The Nhale device draws its power from a durable lithium ion battery. The parts are contained in a compact case for maximum portability.

For more information about retail opportunities or sales, visit **

About Nhale, Inc. (NHLE)

Nhale™ is a technology company that plans to launch commercial products in the consumer space while focusing on two significant trends occurring in the U.S. and around the world:

The adoption of vaporizing and electronic cigarettes, or ecigs, by the world's 1 billion+ smokers, and
The decriminalization and legalization of marijuana for medicinal or recreational purposes.
More information about Nhale is found at **

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of any past success, either financial or strategic, is no guarantee of future success. This news release only speaks as of the date of its distribution.


Contact:
Nhale, Inc.
Lance Williams, 281-671-6877
President and CEO
 
Rodrick R

Posted at lunedì, 21 luglio 2014 14:20
GrowBLOX Sciences, Inc. CEO Updates Shareholders on Key Developments
--Awarded Two Permits, Closed on Capital Raise, Secured Banking Partner, Filled Development Pipeline, Approaching Revenue Generation--

LAS VEGAS, July 21, 2014 /PRNewswire/ --
To Our Shareholders,
Introduction: Much has been happening at GrowBLOX Sciences, Inc. (GBLX) over the past three months, and I wanted to take a moment to update you on our progress. On March 12, 2014, we entered into an asset acquisition agreement that took us to the forefront of the emerging legal cannabis industry. The March agreement gave us intellectual property, equipment, business plans, and other assets that we think will allow us to revolutionize our industry by turning cannabis cultivation from an art into a science.
From Art to Science: Current cannabis cultivation is typically performed without standard methods, scientific scrutiny, or rigorous testing – you might call it a dark art. The invention of our GrowBLOXTM growing chamber seeks to change all this by controlling, standardizing, monitoring, and testing every aspect of cannabis cultivation. We've invested millions of dollars and hired some of the best engineers and botanists to develop this chamber. The chamber is a sealed, sterile environment where computers measure and control everything from temperature, to lighting, to water, to oxygen, to CO2. The result is something like a cannabis factory, where, because you control all the variables, you get consistent, pure, toxin-free strains of cannabis in predictable volumes. You can see a video demo of the chamber on our website, gbsciences.com. To our knowledge, no other company can claim to cultivate high volumes of cannabis with the predictable, standardized outputs that we will achieve.
The GrowBLOX Solution: Not only have we developed our proprietary GrowBLOXTM growing chamber, but also a complete solution to the challenges facing the medical marijuana industry. The full GrowBLOX Solution contains: 1) the GrowBLOXTM tissue propagation chamber for preparing clonally-derived plants; 2) the original GrowBLOXTM growing chamber; 3) the GrowBLOXTM curing chamber to cure and dry each Cannabis harvest; 4) the GrowBLOXTM extraction chamber to create our proprietary oils; 5) GrowBLOXTM branded, childproof packaging for each of the GrowBLOX strains and cannabis-oil based products; and 6) GrowBLOX research supporting the medical efficacy of our products. We don't sell the GrowBLOX Solution to the public or even to the medical marijuana industry. Instead, we will enter strategic partnerships in each state as we rapidly expand.
 
Normand Rexroat

Posted at domenica, 20 luglio 2014 01:24 Visit posters website
A crochet dress is really a appropriate and also ideal choice for this period. It gives convenience as well as fulfillment to someone which wears it. It will offer the convenience of a summer time wear and also the trendy glimpse of a dress. It is also wear on top of a swimsuit easily. There are countless kinds of it, which anytime somebody chooses to put it on, they'd look really modish. It ranges from a basic knitted complete dress to a lot more advanced styles of crochet in each section of a dress. It usually is made of acrylic yarn or perhaps 100 % cotton. Acrylic yarn will offer a more durable gown while the cotton one might search even more sophisticated. But the 100 % cotton needs to be managed with care in cleaning it. Whatever will be your option, crochet dresses are incredibly a lot stylish, trendy and also comfy to use this summer. Have Fun!
 
Blair Woodroof

Posted at sabato, 19 luglio 2014 00:40 Visit posters website
In 1961 Laura Ashley as well as husband Bernard Ashley moved from their Kent house, the first design and creation venue, to Carno, Wales, to enable them to expand the business and stay motivated by the rolling Wales countryside. Their own vintage pieces are now so desired and wanted! - And once you have witnessed and worn their particular garments you'll understand exactly why they are so adored! The Ashleys' scarves speedily became successful with stores, retailing equally by way of mail order and high street stores for example John Lewis - Bernard left his city job to print fabrics full-time. This kind of put them on the road to becoming an international organization with a brand name that is certainly recognized world wide. Laura designed the prints and Bernard built the printing equipment; Laura remained the boss of design until immediately before her death, while Bernard managed the functional side.

 
Jonah Ramberg

Posted at venerdì, 18 luglio 2014 12:30 Visit posters website
What fits the bill for any phone call to lengthy separation movers Los Angeles? Moving one hundred miles far from or to Los Angeles rebelliously warrants a call to a Los Angeles lengthy separation moving administrations supplier. For any viable sort of moving, you'll be able to run having a city mover or any probable neighborhood mover yet Los Angeles moving organization will present for you personally each fortune.I comprehend that moving to LA may not happen to be a basic selection for you. You might be reaching an additional city leaving companions, neighbors behind, and deserting even the group where you existed for such a big number of years, or might be for all your life.
 
Andre Sims

Posted at venerdì, 18 luglio 2014 03:31 Visit posters website
Fantastic reading. I love reading things like this and its what makes the internet great.
 
Simon

Posted at venerdì, 18 luglio 2014 02:49 Visit posters website
I loved this site. Great lay out and easy to navigate. Ten out of ten!
 
Heather

Posted at venerdì, 18 luglio 2014 02:22 Visit posters website
Great reading and I really loved the layout.
 
Katie Newman

Posted at giovedì, 17 luglio 2014 15:45 Visit posters website
Has a Leader Emerged in the Medical MJ Industry?
What’s the Industry Update?

The Medical MJ Industry is developing right before our eyes. The potential investment opportunity of a lifetime is evolving as we speak and legislation is following up fast. So, ask yourself, are you ready for it? Did you know that if MJ was entirely legal today that it would already be an estimated $50 bil market? Are you positioned to capitalize on what could become the biggest industry boom since the Internet or Gold Rush?
If you have familiarized yourself with GrowBLOX Sciences, Inc. (GBLX) then you are certainly on the right path. GBLX remains our #1 Pick in the Medical MJ Industry and seems to be well on their way to establishing themselves as the clear industry leader. A lot has happened with the company and industry since we first profiled them back in mid-May and as an investor or potential investor you MUST fully understand the significance of their achievements and business plan and know why this could truly be the ground-floor opportunity of a lifetime.
Investing in the right company during the Internet Boom generated countless amounts of wealth and created millionaires literally overnight. We believe the same will be said for early investors in the company that emerges as the industry leader in the rapidly growing Medical MJ Industry. If you haven’t done so already, it’s time you strongly considered and began researching GrowBLOX Sciences, Inc. (GBLX).
There’s a laundry list of reasons why we believe GBLX will soon emerge as the first industry leader. Throughout this report you will learn what accomplishments the company has made in executing a business plan truly unique to its competitors while being made aware of industry advancements that have many excited for what is still to come.
6 Things Separating GBLX from All the Rest
1. Permits: GrowBLOX Sciences, Inc. is the only publically traded company to be approved for both a dispensary permit AND a cultivation permit. This fact alone should be enough to intrigue any investor. In this past June, GBLX through its local partnership, GB Sciences Nevada, LLC, completed presentations to the Board of Commissioners in Clark County, Nevada and was successful in acquiring a special use permit for its Fort Apache dispensary and cultivation facility in Las Vegas. This is an enormous milestone that no other public company has been able to accomplish up to this point.

This means that once fully operational, shareholders of GBLX will be able to benefit from the actual growth and sale of medical MJ. While competitors are touting the sale of hemp products, vapor pens, or just plant growth, GBLX is vertically integrated to provide shareholders true Medical MJ Industry exposure. This is one of the main reasons why we believe GBLX will soon emerge as an industry leader.

2. Patent-Pending GrowBLOX™ Cultivation Technology: The GrowBLOX™ Controlled Environment Agricultural Chambers (“GrowBLOX™”) is specifically designed to produce optimal environmental growing conditions for medical MJ cultivation. It is the first chamber of its kind with the ability to monitor and control the growth process in order to produce high-grade medicinal MJ. The cutting-edge GrowBLOX™ hydroponic technology allows for continuous, healthy cycles of MJ plants to reach optimized medicinal potency during the bloom cycle. Each fully enclosed chamber physically isolates each plant to protect from the onset and spread of insect and mite infestations in the grow operation and keep harmful contaminants, such as pesticides, insecticides, and vehicle exhaust out of the medicinal plants growing inside.
The idea is to be able to grow the exact same strain of MJ plant consistently. Think of buying a bottle of Tylenol for a headache. Whether you purchase the bottle in New York or Texas you know that you are getting the exact same kind of Tylenol, it’s consistent. Well, GBLX believes that if the FDA is going to approve medical MJ products, there needs to be a way to consistently grow MJ of the exact same efficacy. This way, patients know that they are getting the exact same medicine no matter where or when they purchase the product.
3. Expanding Operations in Multiple States: GrowBLOX Sciences, Inc. just announced it has entered the Florida Medical MJ Market through its new subsidiary, GB Sciences Florida, LLC. With nearly 20 mil residents, Florida is poised to be the biggest medical MJ market outside of California. National associations estimate medical MJ will be a $785 mil industry in Florida with multiple economic opportunities. Florida is the second state that GBLX has set up shop in after Nevada. The company has plans to continue its rapid expansion by forming various LLCs in several other states with significant medical MJ markets. Having an LLC in each individual state will allow GBLX to generate revenue in multiple medical MJ markets while remaining in full compliance with individual state laws and regulations.

4. Superior Biotechnology & Science: GrowBLOX Sciences, Inc. isn’t just stopping with plant growth and medical MJ dispensary sales. GBLX endeavors to pursue the research, testing, and development of treatment options using the phytocannabinoids present in the cannabis plant. In the near term, GBLX will act as a “virtual biopharmaceutical” to fast-track treatments to market. The accelerated development process will shorten the anticipated time to returns and decrease the estimated cost.

The accelerated development pathway will include: capitalizing on existing cannabinoid patents with promising prototypes and acquiring licenses for those prototypes during animal trials, and proceeding through human clinical trials with a co-development partner while complying with the standard FDA approval processes. The company will then out-license the resulting drug for marketing and sale to a large biopharmaceutical partner.
In addition, a traditional cannabinoid product pipeline will be developed in parallel with the accelerated product development. This will include: screening the 70 cannabinoids present in the cannabis plant in differing combinations derived from various plant strains to determine medical benefit, animal testing of effectiveness of pharmaceutical compositions, and human clinical trials for use in FDA filings. GBLX’s traditional pipeline would allow for enhanced profitability through their ability to capture a greater percentage of the value created through this vertically-integrated approach. In addition, growth in the company’s revenue stream comes through the application of their proprietary extracts to multiple treatment options and expansion into foreign markets. The ability to generate additional revenue from product licensing opportunities can also be explored simultaneously.
Therefore, by utilizing GBLX’s patent-pending cultivation technology and a simultaneous two-phase approach to create a cannabinoid product development pipeline, the company will be able to provide FDA-approved cannabis-therapy options to patients in a shorter time frame, which will also accelerate the time to a return on the company’s investment.
5. Backed by a Financial Institution: Also in June, GrowBLOX Sciences, Inc. announced a Letter of Intent with First Security Bank of Nevada to manage their currency and banking flow from operations. This is a hurdle that most other MJ companies are yet to overcome. First Security Bank of Nevada offers an array of financial services and has agreed to work in conjunction with GBLX to ensure accuracy and consistency with all local, state and federal banking laws.

6. Insider Buying: Lazarus Investment Partners LLLP, acquired an additional 269,632 shares in the open market for an additional $322,000 investment. Lazarus, which already holds a 3 mil share investment, averaged up their position acquiring 199,632 shares at $1.19, 50,000 shares at $1.21, and 20,000 shares at $1.20 over a three day period from June 30, 2014, to July 2, 2014.
Lazarus Investment Partners LLLP increasing their investment by averaging up and acquiring additional shares in the open market shows their belief in GrowBLOX Sciences, Inc. and their ability to execute on their unique business plan. The move also proves that Lazarus considers shares of GrowBLOX Sciences, Inc. to be undervalued. The Company has made substantial headway in becoming a biotechnology leader in the legal cannabis space over the last few months which has given Lazarus the confidence to increase their investment at a higher price.
These 6 points are why we believe GBLX will soon emerge as the clear Medical MJ Industry leader. It’s nearly impossible to find another MJ company with more going for it than GrowBLOX Sciences, Inc. Their assets and achievements are remarkable, but this could be just the beginning.

GrowBLOX Sciences, Inc. was able to achieve all of the above milestones within a few short months. This company is still very young and could represent a truly amazing ground-floor opportunity in the most exciting industry this country has seen since the Internet Boom.
Speaking of the industry, what’s the update there? What has happened since we first labeled GBLX as our #1 Medical MJ Pick?

Why the Timing is Perfect

There have been a few major advancements in the Medical MJ Industry lately that have investors and analysts exciting about how quickly the industry is progressing.

1. May 29, 2014: Minnesota became the 22nd state to legalize the use of medical MJ.

2. May 30, 2014: The U.S. House passed an amendment barring the U.S. Justice Department and the Drug Enforcement Administration from going after medical marijuana operations and users in states where it is legal on a 219 to 189 vote - one vote more than it needed to be approved.

3. June 29, 2014 – July 1, 2014: The first WeedStock Cannabis Investor Conference was held with great success as GrowBLOX Sciences, Inc. CEO, Craig Ellins, gave a speech on the state of the medical MJ industry and explained how he is positioning his company to capitalize on the increased legislation.

4. July 5, 2014: New York became the 23rd state to legalize the use of medical MJ.

5. July 8, 2014: Washington becomes the 2nd state to legalize the use of recreational MJ.

Over the past couple months since we named GBLX as our #1 Medical MJ Pick, the industry as a whole has made tremendous headway as the country has begun to swing in decisive favor of an overall legalization for medical MJ. For the first time since the CBS News Poll began asking the question, more than 50% of Americans are in favor of legalizing the use of medical MJ. 51% are in favor while 34% oppose and 15% are unsure compared to only 27% being in favor in 1979.

The Medical MJ Industry is here to stay. In fact, it’s just barely started and is still in its infancy stage. There is no question that Medical MJ could become the next great American Industry. And early investors in the right company could experience increased wealth only seen in the tech giants to emerge from the Internet Boom.

Could you imagine if you invested in Amazon at its $18 IPO price in 1997? Or how about Apple at $22 in 1980 or Priceline at $16 in 1999? One thing each of these companies has in common is that they are all industry leaders in their respective businesses and have gone on to create massive amounts of wealth for early investors. And we believe that in a few years from now, people will look back to this time and say could you imagine investing in the Medical MJ Industry leader back then. Well ladies and gentlemen, back then is now and this could be your chance at getting involved in a booming industry at the ground floor. This could be your chance to generate massive amounts of wealth by investing in the right Medical MJ Company today.

On the Verge of Something Special

GrowBLOX Sciences, Inc. has so many positive things going for it right now and we only expect the strong press releases to keep coming as the company continues to execute on its business plan and the industry continues to progress as a whole. As the company’s operations advance and they move into other medical MJ approved states, GBLX could quickly distance itself from the other medical MJ companies operating today. No company has captured an overall market share of this infant industry yet and we believe GBLX has the tools and management to be the first.

Being vertically integrated from seed to sale has GBLX positioned to take a strangle hold on the market. Their GrowBLOX™ technology will allow the company to consistently grow the highest efficacy of medical MJ possible while their special use permits for dispensary and cultivation facilities will lead to business licenses allowing them to sell direct to consumers. Still, perhaps the most exciting element of the GrowBLOX Sciences, Inc. business plan is developing pharmaceutical grade medical MJ products to be licensed for sale by large biopharmaceutical companies. We cannot find another MJ company with as many revenue drivers as GBLX.

We hope you found this report update helpful as the Medical MJ Industry continues to grow and evolve. Early investors in the right MJ company could find themselves sitting pretty a lot sooner than originally anticipated. This industry is growing rapidly as are the companies operating within it. And we believe none other to have the type of industry leading potential that we see in GrowBLOX Sciences, Inc.
DISCLAIMER: Pursuant to an agreement between us and SIGNATURE EXPLORATION AND PRODUCTION, we were hired for a 3 month period beginning on 5/23/14 and ending on 8/15/14 to publicly disseminate information about GrowBLOX Sciences., including on the Website and other media including Facebook and Twitter. We were paid $450,000 for or were paid zero shares of unrestricted or restricted common shares. We own zero shares of GrowBLOX Sciences., which we purchased in the open market. We plan to sell the shares of GrowBLOX Sciences. that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of GrowBLOX Sciences. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information about GrowBLOX Sciences.
 
Katie Newman

Posted at giovedì, 17 luglio 2014 15:24 Visit posters website
Has a Leader Emerged in the Medical MJ Industry?
What’s the Industry Update?

The Medical MJ Industry is developing right before our eyes. The potential investment opportunity of a lifetime is evolving as we speak and legislation is following up fast. So, ask yourself, are you ready for it? Did you know that if MJ was entirely legal today that it would already be an estimated $50 bil market? Are you positioned to capitalize on what could become the biggest industry boom since the Internet or Gold Rush?
If you have familiarized yourself with GrowBLOX Sciences, Inc. (GBLX) then you are certainly on the right path. GBLX remains our #1 Pick in the Medical MJ Industry and seems to be well on their way to establishing themselves as the clear industry leader. A lot has happened with the company and industry since we first profiled them back in mid-May and as an investor or potential investor you MUST fully understand the significance of their achievements and business plan and know why this could truly be the ground-floor opportunity of a lifetime.
Investing in the right company during the Internet Boom generated countless amounts of wealth and created millionaires literally overnight. We believe the same will be said for early investors in the company that emerges as the industry leader in the rapidly growing Medical MJ Industry. If you haven’t done so already, it’s time you strongly considered and began researching GrowBLOX Sciences, Inc. (GBLX).
There’s a laundry list of reasons why we believe GBLX will soon emerge as the first industry leader. Throughout this report you will learn what accomplishments the company has made in executing a business plan truly unique to its competitors while being made aware of industry advancements that have many excited for what is still to come.
6 Things Separating GBLX from All the Rest
1. Permits: GrowBLOX Sciences, Inc. is the only publically traded company to be approved for both a dispensary permit AND a cultivation permit. This fact alone should be enough to intrigue any investor. In this past June, GBLX through its local partnership, GB Sciences Nevada, LLC, completed presentations to the Board of Commissioners in Clark County, Nevada and was successful in acquiring a special use permit for its Fort Apache dispensary and cultivation facility in Las Vegas. This is an enormous milestone that no other public company has been able to accomplish up to this point.

This means that once fully operational, shareholders of GBLX will be able to benefit from the actual growth and sale of medical MJ. While competitors are touting the sale of hemp products, vapor pens, or just plant growth, GBLX is vertically integrated to provide shareholders true Medical MJ Industry exposure. This is one of the main reasons why we believe GBLX will soon emerge as an industry leader.

2. Patent-Pending GrowBLOX™ Cultivation Technology: The GrowBLOX™ Controlled Environment Agricultural Chambers (“GrowBLOX™”) is specifically designed to produce optimal environmental growing conditions for medical MJ cultivation. It is the first chamber of its kind with the ability to monitor and control the growth process in order to produce high-grade medicinal MJ. The cutting-edge GrowBLOX™ hydroponic technology allows for continuous, healthy cycles of MJ plants to reach optimized medicinal potency during the bloom cycle. Each fully enclosed chamber physically isolates each plant to protect from the onset and spread of insect and mite infestations in the grow operation and keep harmful contaminants, such as pesticides, insecticides, and vehicle exhaust out of the medicinal plants growing inside.
The idea is to be able to grow the exact same strain of MJ plant consistently. Think of buying a bottle of Tylenol for a headache. Whether you purchase the bottle in New York or Texas you know that you are getting the exact same kind of Tylenol, it’s consistent. Well, GBLX believes that if the FDA is going to approve medical MJ products, there needs to be a way to consistently grow MJ of the exact same efficacy. This way, patients know that they are getting the exact same medicine no matter where or when they purchase the product.
3. Expanding Operations in Multiple States: GrowBLOX Sciences, Inc. just announced it has entered the Florida Medical MJ Market through its new subsidiary, GB Sciences Florida, LLC. With nearly 20 mil residents, Florida is poised to be the biggest medical MJ market outside of California. National associations estimate medical MJ will be a $785 mil industry in Florida with multiple economic opportunities. Florida is the second state that GBLX has set up shop in after Nevada. The company has plans to continue its rapid expansion by forming various LLCs in several other states with significant medical MJ markets. Having an LLC in each individual state will allow GBLX to generate revenue in multiple medical MJ markets while remaining in full compliance with individual state laws and regulations.

4. Superior Biotechnology & Science: GrowBLOX Sciences, Inc. isn’t just stopping with plant growth and medical MJ dispensary sales. GBLX endeavors to pursue the research, testing, and development of treatment options using the phytocannabinoids present in the cannabis plant. In the near term, GBLX will act as a “virtual biopharmaceutical” to fast-track treatments to market. The accelerated development process will shorten the anticipated time to returns and decrease the estimated cost.

The accelerated development pathway will include: capitalizing on existing cannabinoid patents with promising prototypes and acquiring licenses for those prototypes during animal trials, and proceeding through human clinical trials with a co-development partner while complying with the standard FDA approval processes. The company will then out-license the resulting drug for marketing and sale to a large biopharmaceutical partner.
In addition, a traditional cannabinoid product pipeline will be developed in parallel with the accelerated product development. This will include: screening the 70 cannabinoids present in the cannabis plant in differing combinations derived from various plant strains to determine medical benefit, animal testing of effectiveness of pharmaceutical compositions, and human clinical trials for use in FDA filings. GBLX’s traditional pipeline would allow for enhanced profitability through their ability to capture a greater percentage of the value created through this vertically-integrated approach. In addition, growth in the company’s revenue stream comes through the application of their proprietary extracts to multiple treatment options and expansion into foreign markets. The ability to generate additional revenue from product licensing opportunities can also be explored simultaneously.
Therefore, by utilizing GBLX’s patent-pending cultivation technology and a simultaneous two-phase approach to create a cannabinoid product development pipeline, the company will be able to provide FDA-approved cannabis-therapy options to patients in a shorter time frame, which will also accelerate the time to a return on the company’s investment.
5. Backed by a Financial Institution: Also in June, GrowBLOX Sciences, Inc. announced a Letter of Intent with First Security Bank of Nevada to manage their currency and banking flow from operations. This is a hurdle that most other MJ companies are yet to overcome. First Security Bank of Nevada offers an array of financial services and has agreed to work in conjunction with GBLX to ensure accuracy and consistency with all local, state and federal banking laws.

6. Insider Buying: Lazarus Investment Partners LLLP, acquired an additional 269,632 shares in the open market for an additional $322,000 investment. Lazarus, which already holds a 3 mil share investment, averaged up their position acquiring 199,632 shares at $1.19, 50,000 shares at $1.21, and 20,000 shares at $1.20 over a three day period from June 30, 2014, to July 2, 2014.
Lazarus Investment Partners LLLP increasing their investment by averaging up and acquiring additional shares in the open market shows their belief in GrowBLOX Sciences, Inc. and their ability to execute on their unique business plan. The move also proves that Lazarus considers shares of GrowBLOX Sciences, Inc. to be undervalued. The Company has made substantial headway in becoming a biotechnology leader in the legal cannabis space over the last few months which has given Lazarus the confidence to increase their investment at a higher price.
These 6 points are why we believe GBLX will soon emerge as the clear Medical MJ Industry leader. It’s nearly impossible to find another MJ company with more going for it than GrowBLOX Sciences, Inc. Their assets and achievements are remarkable, but this could be just the beginning.

GrowBLOX Sciences, Inc. was able to achieve all of the above milestones within a few short months. This company is still very young and could represent a truly amazing ground-floor opportunity in the most exciting industry this country has seen since the Internet Boom.
Speaking of the industry, what’s the update there? What has happened since we first labeled GBLX as our #1 Medical MJ Pick?

Why the Timing is Perfect

There have been a few major advancements in the Medical MJ Industry lately that have investors and analysts exciting about how quickly the industry is progressing.

1. May 29, 2014: Minnesota became the 22nd state to legalize the use of medical MJ.

2. May 30, 2014: The U.S. House passed an amendment barring the U.S. Justice Department and the Drug Enforcement Administration from going after medical marijuana operations and users in states where it is legal on a 219 to 189 vote - one vote more than it needed to be approved.

3. June 29, 2014 – July 1, 2014: The first WeedStock Cannabis Investor Conference was held with great success as GrowBLOX Sciences, Inc. CEO, Craig Ellins, gave a speech on the state of the medical MJ industry and explained how he is positioning his company to capitalize on the increased legislation.

4. July 5, 2014: New York became the 23rd state to legalize the use of medical MJ.

5. July 8, 2014: Washington becomes the 2nd state to legalize the use of recreational MJ.

Over the past couple months since we named GBLX as our #1 Medical MJ Pick, the industry as a whole has made tremendous headway as the country has begun to swing in decisive favor of an overall legalization for medical MJ. For the first time since the CBS News Poll began asking the question, more than 50% of Americans are in favor of legalizing the use of medical MJ. 51% are in favor while 34% oppose and 15% are unsure compared to only 27% being in favor in 1979.

The Medical MJ Industry is here to stay. In fact, it’s just barely started and is still in its infancy stage. There is no question that Medical MJ could become the next great American Industry. And early investors in the right company could experience increased wealth only seen in the tech giants to emerge from the Internet Boom.

Could you imagine if you invested in Amazon at its $18 IPO price in 1997? Or how about Apple at $22 in 1980 or Priceline at $16 in 1999? One thing each of these companies has in common is that they are all industry leaders in their respective businesses and have gone on to create massive amounts of wealth for early investors. And we believe that in a few years from now, people will look back to this time and say could you imagine investing in the Medical MJ Industry leader back then. Well ladies and gentlemen, back then is now and this could be your chance at getting involved in a booming industry at the ground floor. This could be your chance to generate massive amounts of wealth by investing in the right Medical MJ Company today.

On the Verge of Something Special

GrowBLOX Sciences, Inc. has so many positive things going for it right now and we only expect the strong press releases to keep coming as the company continues to execute on its business plan and the industry continues to progress as a whole. As the company’s operations advance and they move into other medical MJ approved states, GBLX could quickly distance itself from the other medical MJ companies operating today. No company has captured an overall market share of this infant industry yet and we believe GBLX has the tools and management to be the first.

Being vertically integrated from seed to sale has GBLX positioned to take a strangle hold on the market. Their GrowBLOX™ technology will allow the company to consistently grow the highest efficacy of medical MJ possible while their special use permits for dispensary and cultivation facilities will lead to business licenses allowing them to sell direct to consumers. Still, perhaps the most exciting element of the GrowBLOX Sciences, Inc. business plan is developing pharmaceutical grade medical MJ products to be licensed for sale by large biopharmaceutical companies. We cannot find another MJ company with as many revenue drivers as GBLX.

We hope you found this report update helpful as the Medical MJ Industry continues to grow and evolve. Early investors in the right MJ company could find themselves sitting pretty a lot sooner than originally anticipated. This industry is growing rapidly as are the companies operating within it. And we believe none other to have the type of industry leading potential that we see in GrowBLOX Sciences, Inc.
DISCLAIMER: Pursuant to an agreement between us and SIGNATURE EXPLORATION AND PRODUCTION, we were hired for a 3 month period beginning on 5/23/14 and ending on 8/15/14 to publicly disseminate information about GrowBLOX Sciences., including on the Website and other media including Facebook and Twitter. We were paid $450,000 for or were paid zero shares of unrestricted or restricted common shares. We own zero shares of GrowBLOX Sciences., which we purchased in the open market. We plan to sell the shares of GrowBLOX Sciences. that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of GrowBLOX Sciences. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information about GrowBLOX Sciences.
 
Syble Gloster

Posted at mercoledì, 16 luglio 2014 22:35 Visit posters website
In 1961 Laura Ashley and husband Bernard Ashley moved from their Kent house, the initial style and also production venue, to Carno, Wales, in order to increase the business and stay motivated by the rolling Wales countryside. Their own vintage pieces are actually so desired and desired! - And also once you have observed and worn their clothes you may know why they may be so esteemed! The Ashleys' scarves speedily became successful with stores, retailing each through mail order and also high street restaurants for instance John Lewis - Bernard left his city job to print fabrics full-time. This kind of put them on the road to becoming a global company with a manufacturer that's recognized over the world. Laura designed the prints and Bernard developed the printing gear; Laura continued to be responsible for design and style until soon prior to her death, whilst Bernard managed the detailed side.

 
Aurelio Fiato

Posted at mercoledì, 16 luglio 2014 22:09 Visit posters website
A crochet dress is really a appropriate and also perfect choice for this season. It gives comfort as well as fulfillment to somebody who wears it. It'll provide capability of a summer time put on as well as the fashionable glimpse of a dress. It's also put on on top of a swimsuit effortlessly. There are a lot of types of it, that anytime somebody selects to put it on, they would search really modish. It ranges from a simple knitted entire dress to much more complex designs of crochet in every portion of a dress. It can be made of acrylic yarn or perhaps cotton. Acrylic yarn will offer an increasingly durable dress while the 100 % cotton one might appear a lot more sophisticated. But the natural cotton needs to be dealt with carefully in washing it. Whatever will be your choice, crochet dresses are very significantly fashionable, stylish as well as comfy to wear this summer. Have Fun!
 
Katie Newman

Posted at mercoledì, 16 luglio 2014 20:12 Visit posters website
GrowBLOX Sciences, Inc. Enters the Florida Medical Marijuana Market

LAS VEGAS, July 16, 2014 /PRNewswire/ -- GrowBLOX Sciences, Inc. (GBLX) a medical marijuana research and development company, is pleased to announce it has entered the Florida Medical Marijuana Market through its new subsidiary, GB Sciences Florida, LLC. With nearly 20 million residents, Florida is poised to be the biggest medical marijuana market outside of California. The National Cannabis Industry Association estimates medical marijuana will be a $785 million industry in Florida with multiple economic opportunities. In November, Florida voters will decide if they should allow widespread sale and use of medical cannabis by saying "yay" or "nay" on The Florida Right to Medical Marijuana Initiative, commonly known as Amendment 2. Early polls show that voters are likely to approve the ballot as all expectations are for a landslide approval. If and when Florida approves the bill, it will become the first state in the Southeast to do so.

Furthermore, GrowBLOX Sciences recognizes Florida's high standards for quality in medical marijuana cultivation as a perfect match for their GrowBLOX™ cultivation technology. GrowBLOX CEO, Craig Ellins, said, "In an effort to safeguard Florida's medical marijuana patients, Florida's legislators have crafted some of the country's most stringent quality standards when it comes to the safety and efficacy of the medical marijuana grown in their state. They want medical solutions, and that's exactly what our GrowBLOX™ does, it makes medicine."

The GrowBLOX™ cultivation chamber is uniquely designed to produce medical marijuana with consistent potency from harvest to harvest. Medical marijuana grown in our GrowBLOX™ is also completely shielded from harmful pesticides, insecticides, and other pollutants. This provides medical marijuana patients with peace of mind knowing that they are receiving the same quality and quantity of active compounds within our medicinal marijuana with each use. Mr. Ellins made this comparison, "Think of when you buy a bottle of over the counter medication. Whether you buy that medication in New York or Texas, you know that you are getting the exact same medication no matter where or when you buy it. That is the idea behind the GrowBLOX™ cultivation system. Plants grown through other grow conditions will have harvest to harvest inconsistencies. We want our customers to know that they are getting the same medicine each and every time."

About GrowBLOX Sciences, Inc.

GrowBLOX Sciences, Inc., is a research and development company that has proprietary indoor growing chambers specifically designed for medical cannabis cultivation. The GrowBLOX™ chamber allows for completely controlled growing conditions, ensuring the manufacture of a consistent, toxin-free, natural and medicinal-grade product. The Company believes that the advantages of a controlled environment over traditional outdoor or greenhouse growing, will empower the public, nutraceutical and pharmaceutical industries to embrace cannabis as an effective treatment for a myriad of serious medical conditions.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Jonathan Barkman
Riverview Capital Enterprises
+1-866-845-0105
 
Katie Newman

Posted at mercoledì, 16 luglio 2014 19:34 Visit posters website
GrowBLOX Sciences, Inc. Enters the Florida Medical Marijuana Market

LAS VEGAS, July 16, 2014 /PRNewswire/ -- GrowBLOX Sciences, Inc. (GBLX) a medical marijuana research and development company, is pleased to announce it has entered the Florida Medical Marijuana Market through its new subsidiary, GB Sciences Florida, LLC. With nearly 20 million residents, Florida is poised to be the biggest medical marijuana market outside of California. The National Cannabis Industry Association estimates medical marijuana will be a $785 million industry in Florida with multiple economic opportunities. In November, Florida voters will decide if they should allow widespread sale and use of medical cannabis by saying "yay" or "nay" on The Florida Right to Medical Marijuana Initiative, commonly known as Amendment 2. Early polls show that voters are likely to approve the ballot as all expectations are for a landslide approval. If and when Florida approves the bill, it will become the first state in the Southeast to do so.

Furthermore, GrowBLOX Sciences recognizes Florida's high standards for quality in medical marijuana cultivation as a perfect match for their GrowBLOX™ cultivation technology. GrowBLOX CEO, Craig Ellins, said, "In an effort to safeguard Florida's medical marijuana patients, Florida's legislators have crafted some of the country's most stringent quality standards when it comes to the safety and efficacy of the medical marijuana grown in their state. They want medical solutions, and that's exactly what our GrowBLOX™ does, it makes medicine."

The GrowBLOX™ cultivation chamber is uniquely designed to produce medical marijuana with consistent potency from harvest to harvest. Medical marijuana grown in our GrowBLOX™ is also completely shielded from harmful pesticides, insecticides, and other pollutants. This provides medical marijuana patients with peace of mind knowing that they are receiving the same quality and quantity of active compounds within our medicinal marijuana with each use. Mr. Ellins made this comparison, "Think of when you buy a bottle of over the counter medication. Whether you buy that medication in New York or Texas, you know that you are getting the exact same medication no matter where or when you buy it. That is the idea behind the GrowBLOX™ cultivation system. Plants grown through other grow conditions will have harvest to harvest inconsistencies. We want our customers to know that they are getting the same medicine each and every time."

About GrowBLOX Sciences, Inc.

GrowBLOX Sciences, Inc., is a research and development company that has proprietary indoor growing chambers specifically designed for medical cannabis cultivation. The GrowBLOX™ chamber allows for completely controlled growing conditions, ensuring the manufacture of a consistent, toxin-free, natural and medicinal-grade product. The Company believes that the advantages of a controlled environment over traditional outdoor or greenhouse growing, will empower the public, nutraceutical and pharmaceutical industries to embrace cannabis as an effective treatment for a myriad of serious medical conditions.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Jonathan Barkman
Riverview Capital Enterprises
+1-866-845-0105
 
Davis Walicki

Posted at mercoledì, 16 luglio 2014 00:24 Visit posters website
Without the need of excellent-hunting hair, your entire day is frequently shot. Bad hair time can certainly make your daily life dismal, therefore making you question everything you devote everything dollars for. If you want to get the very best from your your hair, and keep the life span of this, read through ahead for many excellent tips.
 
Bryanna Wiklund

Posted at martedì, 15 luglio 2014 08:00 Visit posters website
Crochet is one of the oldest techniques used in creating different clothes, bags and even accessories. Crochet dresses really provides exemplary convenience to its wearer, creating it extremely adorable.Back in the early years of crochet, the only people who were able to afford this kind of material were the wealthy. That is the reason why cultural status is also decided by crochet dresses.
 
Louis Junkins

Posted at lunedì, 14 luglio 2014 19:57 Visit posters website
Right now, just like back then, girls want to attend that will celebration and dance the night away. Nonetheless, if you do go to the Halloween celebration in Flapper style dress, it really is vitally important that you seem the portion. If you are interested in a flapper dress for any fancy dress get together that you have coming, then you should look at generating your own. This is often a quite simple process if you find the proper Flapper style dress styles to help you on your way. One example of a simple dress pattern which dates back to the early on 1920s whenever it was at first printed is called the One Hour Dress Pattern.
 
Raymonde Otten

Posted at lunedì, 14 luglio 2014 18:48 Visit posters website
It is excellent to getfamiliar with thedifferent kinds of vintage leather jackets that are attainable, so that while you go to order one you willunderstand what you arechoosing. Very first off, itcould be great for you to understand what theterm vintage is really mentioning to. Quite a few individualsassume that it is just simply a style or a title builtup for a particularstyle of clothing that look aspecified technique. Actually it ismentioning to something from a earlierera. So whenever a vintage leather jacket is referred to it is one from decadesformer. There are threestrategies that you may possibly find out this kind of jacketintroduced to.
 

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Slide Show Pict
Visitors: 2526700